Research Information System
WASOG 2018, Girit, Greece, 7 - 09 June 2018, pp.53
AIM: Pirfenidone is a novel antifibrotic drug for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the safety and efficacy of pirfenidone in patients with mild-to-moderate IPF in clinical practice.
METHODOLOGY: This was a single-center, retrospective, real-life, observational study for IPF patients who received pirfenidone treatment.
RESULTS: Thirty four patients with IPF receiving pirfenidone (76,5% male, mean age 66,7± 9) were analysed in respect to side effects. 14 (41%) patients had side effects, 2 (5%) patients discontinued treatment because of intolerance. Nausea (17.6%) and weigth loss (14.7%) were the most common side effects. Others were heartburn (11.7%), liver enzyme elevation (8.8%), diarrhea (5.8%) and photosensitivity (3.1%). Five (14.7%) patients needed dose adjustment. We performed the efficacy analysis in 29 patients who were received pirfenidone therapy at least six months. Mean treatment duration was 8.2±5.6 months. Mean FVC (%) was 71.2± 16.0, mean DLCO (%) was 53.8±19.1, mean 6MWT (m) was 300±142.3, mean resting SaO2(%) was 93.6±5.2 and mean minSaO2 (%) after 6MWT was 88.7±3.8. After pirfenidone treatment FVC remained stable, while DLCO and 6MWT were improved.
CONCLUSIONS: The present results indicate that pirfenidone treatment is tolerable and effective in IPF in real life setting.